BioPharmaFocus on the pharmaceutical and biotech industry
- Daniel de Boer Discusses His Company’s Focus on Leber Congenital Amaurosis
Daniel de Boer, Founder and CEO of ProQR, discusses his company’s focus on Leber congenital amaurosis. This rare eye disorder primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color.
- ELX-02: Emerging Therapy for Cystic Fibrosis
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals provides an overview of his company’s leading drug candidate, ELX-02 for cystic fibrosis.
- Alexion Submits BLA For Priority Review And Approval Of ALXN1210
Alexion Pharmaceuticals has submitted a Biologics License Application (BLA) to the YOU.S. Food and Drug Administration (FDA) for approval of ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, potentially deadly disease of the blood.T
- Hereditary Xerocytosis Overview
Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses Hereditary Xerocytosis, a genetic disorder in which red blood cells become dehydrated due to loss of potassium and cell water.
- Eloxx Pharmaceuticals and It’s Focus on Cystic Fibrosis
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals provides an overview of his company and it’s focus on cystic fibrosis.
- Chris Garabedian Discusses Xontogeny
Chris Garabedian discusses his new compay, Xontogeny, a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases.
- John Maraganore Speaks Out on His Role as Bio Chair
Dr. John Maraganore has served as the CEO and a Director of Alnylam since 2002 and is the Chair of the Biotechnology Innovation Organization (BIO) for the 2017-2018 term. Dr. John Maraganore has led a career pursuing therapies to address unmet medical …
- BioPharma ProQR Provides a Company Overview
Daniel de Boer, Founder and CEO of ProQR, provides an overview of his company. ProQR’s focus is on diseases that are very severe or life threatening, and have limited treatment options.
- Corbus Pharma Discusses Award from the Cystic Fibrosis Foundation
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses the Development Award from the Cystic Fibrosis Foundation.
- Children’s Tumor Foundation
Annette Bakker, PhD, President and Chief Scientific Officer, of the Children’s Tumor Foundation discusses how her company works with the pharma and biotech industries, specifically SpringWorks Therapeutics.